ADIL - CIK 0001513525
The table below shows ADIAL PHARMACEUTICALS, INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $432.53K | $521.07K | $732.32K | $746.89K | $1.03M | $1.01M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.57M |
| $1.24M |
| $1.15M |
| $1.52M |
| $1.18M |
| $1.27M |
| Operating income | -$2.00M | -$1.76M | -$1.88M | -$2.27M | -$2.21M | -$2.29M |
| Income tax | - | - | - | - | - | - |
| Net income | -$2.02M | -$1.79M | -$1.96M | -$2.23M | -$2.19M | -$2.46M |
| EPS (diluted) | -$1.48 | -$0.08 | -$0.18 | -$8.52 | -$0.38 | -$0.59 |